



Acutus Medical, Inc. Announces Issuance of a New Patent on Dipole Density Mapping on Heart Walls

April 23, 2013

SAN DIEGO, [look](#) CA.—Acutus Medical announced the issuance of U.S. Patent number [8click](#) 417, 313 which relates to the method and device for determining and presenting surface charge and dipole density on cardiac walls.

This patent focuses on an innovative method in cardiac electrophysiology and demonstrates Acutus Medical's leadership in developing novel technologies for mapping the true electrical source of the heart wall's electrical activation." Randy Werneth, President and Chief Executive Officer stated. "This is another example of the importance of our intellectual property strategy as we continue to actively protect the enhanced mapping technologies. Over the past eighteen months, Acutus Medical has filed over 25 patent inventions.

This is the first patent issued relating to Acutus Medical's new imaging and mapping technology.

About Acutus Medical

Since June, 2011, Acutus Medical has pioneered a new and novel approach in the minimally invasive imaging and mapping of cardiac arrhythmias.

Acutus Medical has concentrated its efforts on developing its technology for the treatment of an aberrant arrhythmia, atrial fibrillation (AF). AF is an uncontrollable, rapid, heartbeat that results in a significant decline in the quality of life and may lead to serious complications such as stroke or heart failure. Globally, in excess of 10 million people are afflicted with AF. Pharmacological therapy is the most common current treatment option, but it is expensive, often inadequate, is palliative in nature, and does not cure AF.

Acutus Medical believes that its technology may eventually play a significant role in improving the lives of countless individuals who are afflicted by AF.

This press release includes forward-looking statements regarding Acutus Medical Cardiac Imaging and Mapping Technology System. Any statement describing Acutus Medical's goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Acutus goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing products and in the endeavor of building a business around such products. Acutus Medical's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Acutus Medical forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Acutus Medical. As a result, you are cautioned not to rely on these forward-looking statements.

Download PDF of this press release:

PDF Press Release: Acutus Medical, Inc. Announces Issuance of a New Patent on Dipole Density Mapping on Heart Walls

For More Information, please contact:

Acutus Medical
Mr. Randy Werneth
CEO / President